|
|
Article: Clinic Roundup.
- Article from:
- BIOWORLD Today
- Article date:
- November 3, 2009
CopyrightCOPYRIGHT 2009 A Thomson Healthcare Company. This material is published under license from the publisher through the Gale Group, Farmington Hills, Michigan. All inquiries regarding rights should be directed to the Gale Group. (Hide copyright information)
|
o Accentia Biopharmaceuticals Inc., of Tampa, Fla., reported an interim analysis from blinded data on patients who have completed the 16-week Phase III placebo-controlled trial of SinuNase for the treatment of refractory chronic sinusitis. Based on analysis of more than 80 patients who have completed the trial at 16 weeks, the study has shown improvement in polyposis by endoscopy in about 50 percent of patients and improvement in sinus inflammation by CT scan in about 50 percent of patients. Moreover, the interim data showed almost 50 percent of patients with objective evidence of improvement achieved the primary endpoint of complete resolution of the two key cardinal ...